Sergliflozin etabonate, with the codename GW869682X and an INN and USAN designation, is an investigational anti-diabetic drug that was being developed by GlaxoSmithKline. According to its encyclopedia article it did not undergo further development after phase II. It is recorded here as an investigational compound, noted for what is held about it by its source rather than for any approved use, and the lead does not state any approval. This entry is a record of the source lead only and is not medical advice.
Facts
Classification
Approval StatusInvestigational / Clinical Trial 1 Sources
1. Sergliflozin etabonate (Wikipedia)
Lead paragraphQuote, Lead paragraph
is an investigational anti-diabetic drug being developed by GlaxoSmithKline
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.